Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results